Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE: filgrastim
INDICATION: neutropenia
DATE: 18/09/2014
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
